This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Centene (CNC) Q2 Earnings Miss on Declining Medicaid Membership
by Zacks Equity Research
Centene's (CNC) second-quarter earnings suffer from rising operating expenses and a decline in Medicaid membership levels. Improved Marketplace membership growth partially offset the negatives.
Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Q2 Earnings Season Scorecard and Analyst Reports for Netflix, Wells Fargo & Comcast
by Sheraz Mian
Today's Research Daily features a real-time update on the Q2 earnings season and new research reports on Netflix (NFLX), Wells Fargo (WFC) and Comcast (CMCSA) and others.
Community Health (CYH) Q2 Earnings Miss on Lower Patient Days
by Zacks Equity Research
Community Health's (CYH) second-quarter earnings suffer a setback from lower admissions and patient days. Improved occupancy levels partially offset the negatives.
Universal Health (UHS) Q2 Earnings Beat on Acute Care Strength
by Zacks Equity Research
Universal Health's (UHS) second-quarter results benefit from the rising number of patients in the Acute Care Unit. Declining admissions in the Behavioral Health segment partially offset the positives.
Here's Why HCA Healthcare (HCA) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Tenet Healthcare Corporation (THC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bet on These 5 Attractive Relative Price Strength Plays
by Nilanjan Choudhury
STX, RGA, HCA, IP and OSW are five stocks with explosive relative price strength.
Tenet (THC) Q2 Earnings Beat on Patient Volumes, '24 EPS View Up
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 results reflect net revenue per case growth, higher pricing yield and a decline in overall expenses. It expects 2024 adjusted EPS within $10.41-$11.12, up from the previous guidance of $8.37-$9.41.
2 Standout Stocks to Buy After Beating Earnings Expectations
by Shaun Pruitt
Now looks like a promising time to invest in the increased profitability of HCA Healthcare (HCA) and Spotify Technology (SPOT) after beating Q2 earnings expectations on Tuesday.
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
by Zacks Equity Research
HCA Healthcare (HCA) increases its 2024 EPS in the range of $21.60-$22.8, the midpoint implying growth of 17% from the 2023 figure.
Compared to Estimates, HCA (HCA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
HCA Healthcare (HCA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 10.66% and 2.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release
by Zacks Equity Research
Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.
Buying Tenet (THC) Pre-Q2 Earnings: A Prescription for Profits?
by Kaibalya Pravo Dey
Tenet Healthcare's (THC) second-quarter earnings are likely to have benefited from higher admissions, average length of stay and patient days.
Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings
by Zacks Equity Research
Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.
What's in Store for Texas Instruments (TXN) in Q2 Earnings?
by Zacks Equity Research
Texas Instruments' (TXN) second-quarter 2024 results are likely to reflect the adverse impacts of a weak demand environment and increasing manufacturing costs.
4 Healthcare Stocks Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Expanding aging population and the increasing demand for affordable health products are likely to have boosted the performance of healthcare stocks in Q2. CI, UHS, HCA & THC are potential outperformers.
Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.
Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings
by Zacks Equity Research
Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.
Can HCA Healthcare (HCA) Beat Q2 Earnings on Growing Admissions?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.